Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 98

1.

Management of radial artery perforation during transradial catheterization using a polytetrafluoroethylene covered coronary stent.

Chatterjee A, White JS, Leesar MA.

Cardiovasc Revasc Med. 2016 Aug 15. pii: S1553-8389(16)30199-3. doi: 10.1016/j.carrev.2016.08.002. [Epub ahead of print]

PMID:
27591152
2.

Comprehensive review on cardio-oncology: Role of multimodality imaging.

Chen-Scarabelli C, McRee C, Leesar MA, Hage FG, Scarabelli TM.

J Nucl Cardiol. 2016 May 25. [Epub ahead of print]

PMID:
27225513
3.

Safety of hydrophilic guidewires used for side-branch protection during stenting and proximal optimization technique in coronary bifurcation lesions.

Chatterjee A, Brott BC, Foley R, Alli O, Sasse M, Ahmed M, Al Solaiman F, Reddy G, Ather S, Leesar MA.

Cardiovasc Revasc Med. 2016 Apr 22. pii: S1553-8389(16)30110-5. doi: 10.1016/j.carrev.2016.04.006. [Epub ahead of print]

PMID:
27210866
4.

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.

Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators.

JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. Erratum in: JAMA. 2016 Jul 19;316(3):350.

5.

Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas K, Leesar MA, Grines CL, Marmagkiolis K.

Circulation. 2016 Mar 29;133(13):1272-89. doi: 10.1161/CIRCULATIONAHA.115.018347. Review.

PMID:
27022039
6.

Comparison of failure rates of crossing side branch with pressure vs. coronary guidewire: a meta-analysis.

Ather S, Bavishi CP, Bhatia V, Bajaj NS, Leesar MA.

Eur J Clin Invest. 2016 May;46(5):448-59. doi: 10.1111/eci.12620. Epub 2016 Apr 15.

PMID:
26990307
7.

A Risk-Scoring Model to Predict One-year Major Adverse Cardiac Events after Percutaneous Coronary Intervention.

Kassaian SE, Saroukhani S, Alaeddini F, Salarifar M, Capodanno D, Poorhoseini H, Lotfi-Tokaldany M, Leesar MA, Aghajani H, Hakki-Kazzazi E, Alidoosti M, Haji-Zeinali AM, Saifi M, Nematipour E.

J Tehran Heart Cent. 2015 Oct 27;10(4):167-75.

8.

Impact of Transcatheter Aortic Valve Replacement on Surgical Volumes and Outcomes in a Tertiary Academic Cardiac Surgical Practice.

Davies JE Jr, McAlexander WW, Sasse MF, Leesar MA, Melby SJ, Singh SP, Jernigan LB, Booker OJ, Alli OO.

J Am Coll Surg. 2016 Apr;222(4):645-55. doi: 10.1016/j.jamcollsurg.2015.12.054. Epub 2016 Jan 14.

PMID:
26905186
9.

U.S. Trends in Inpatient Utilization of Fractional Flow Reserve and Percutaneous Coronary Intervention.

Pothineni NV, Shah NS, Rochlani Y, Nairooz R, Raina S, Leesar MA, Uretsky BF, Hakeem A.

J Am Coll Cardiol. 2016 Feb 16;67(6):732-3. doi: 10.1016/j.jacc.2015.11.042. No abstract available.

PMID:
26868697
10.

SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista).

Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas KP, Leesar MA, Marmagkiolis K.

Catheter Cardiovasc Interv. 2016 Apr;87(5):E202-23. doi: 10.1002/ccd.26379. Epub 2016 Jan 12.

PMID:
26756277
11.

SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologıa Intervencionista).

Iliescu C, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas K, Leesar MA, Marmagkiolis K.

Catheter Cardiovasc Interv. 2016 Apr;87(5):895-9. doi: 10.1002/ccd.26375. Epub 2015 Dec 23.

PMID:
26700403
12.

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators.

N Engl J Med. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12.

13.

Diagnostic cutoff for pressure drop coefficient in relation to fractional flow reserve and coronary flow reserve: A patient-level analysis.

Kolli KK, van de Hoef TP, Effat MA, Banerjee RK, Peelukhana SV, Succop P, Leesar MA, Imran A, Piek JJ, Helmy TA.

Catheter Cardiovasc Interv. 2016 Feb 1;87(2):273-82. doi: 10.1002/ccd.26063. Epub 2015 Oct 1.

PMID:
26424295
14.

The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.

Alsidawi S, Effat M, Rahman S, Abdallah M, Leesar M.

Cardiovasc Ther. 2015 Dec;33(6):360-6. doi: 10.1111/1755-5922.12160.

PMID:
26363283
15.

Letter by Reddy and Leesar Regarding Article "Assisted Beating of the Ischemic Heart: How to Manage the Pulseless ST-Segment-Elevation Myocardial Infarction Patient".

Reddy G, Leesar M.

Circulation. 2015 Jun 16;131(24):e533. doi: 10.1161/CIRCULATIONAHA.114.013982. No abstract available.

16.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.

17.

Glycoprotein IIb/IIIa inhibitors improve mortality after aspiration thrombectomy in patients with ST-segment elevation myocardial infarction.

Bajaj NS, Ather S, Gaba S, Aggarwal H, Arora P, Ghimire G, Bhatia V, Parashar A, Ahmed MI, Ahmed A, Leesar MA.

Int J Cardiol. 2015;187:206-7. doi: 10.1016/j.ijcard.2015.03.173. Epub 2015 Mar 17. No abstract available.

PMID:
25839623
18.

Coronary bifurcation lesions: Present status and future perspectives.

Leesar MA, Hakeem A, Azarnoush K, Thuesen L.

Int J Cardiol. 2015;187:48-57. doi: 10.1016/j.ijcard.2015.03.183. Epub 2015 Mar 18. Review.

PMID:
25828312
19.

Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators.

JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. Erratum in: JAMA. 2016 Jul 5;316(1):105. JAMA. 2016 Jul 5;316(1):105. JAMA. 2015 Jun 2;313(21):2185.

20.

Transcatheter aortic valve replacement program in the post-food and drug administration approval era: early outcomes at an academic medical center.

Melby SJ, Bess KM, Isbell KD, Sasse MF, Leesar MA, Alli OO, Singh SP, Jernigan LB, George JF, Davies JE.

Innovations (Phila). 2015 Jan-Feb;10(1):48-51. doi: 10.1097/IMI.0000000000000121.

PMID:
25628252
Items per page

Supplemental Content

Loading ...
Write to the Help Desk